// App-Quantinova.ai

: Dupilumab Significantly Improves Sleep Disturbance in Adults with Moderate-to-Severe Atopic Dermatitis: Results of the DUPISTAD study

Researchers

Presenter

  • Joseph F. Merola

Principal Investigators

  • Albert S. Chiou

  • Emmanuel During

  • Antonio Costanzo

  • Peter Foley

  • Marius Ardeleanu

  • Minzhi Liu

  • Zafer E. Ozturk

Medical Centers

  • Brigham and Women's Hospital and Harvard Medical School, Boston, MA

  • Stanford Univ, Palo Alto, CA

  • Humanitas University, Rozzano, Italy

  • Skin Health Institute, Carlton, VIC, Australia

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY

  • Tigermed-BDM, Frederick, MD, USA

  • Sanofi Genzyme, Cambridge, USA

Locations

  • Australia

  • United States

  • Italy

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

Disease

  • Atopic Dermatitis

Biomarkers

  • Nutritional risk screening

Drug/Treatment

  • Dupilumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • I

Study Id's

  • NCT04033367

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved